KLP Kapitalforvaltning AS Sells 5,500 Shares of Gilead Sciences, Inc. $GILD

KLP Kapitalforvaltning AS lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 790,808 shares of the biopharmaceutical company’s stock after selling 5,500 shares during the quarter. KLP Kapitalforvaltning AS owned approximately 0.06% of Gilead Sciences worth $97,064,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Corundum Trust Company INC bought a new position in Gilead Sciences in the third quarter worth approximately $26,000. Financial Consulate Inc. grew its stake in Gilead Sciences by 85.8% in the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 109 shares in the last quarter. MTM Investment Management LLC grew its stake in Gilead Sciences by 176.0% in the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 176 shares in the last quarter. BOCHK Asset Management Ltd bought a new position in Gilead Sciences in the fourth quarter worth approximately $31,000. Finally, Millstone Evans Group LLC lifted its holdings in Gilead Sciences by 58.7% during the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 118 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Friday, February 27th. The stock was sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the completion of the sale, the chief executive officer owned 642,308 shares in the company, valued at approximately $92,999,775.32. This represents a 1.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total value of $422,880.00. Following the sale, the insider owned 128,779 shares of the company’s stock, valued at approximately $18,152,687.84. This represents a 2.28% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 294,280 shares of company stock worth $42,302,950. Insiders own 0.30% of the company’s stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Zacks highlights Gilead as a long-term value pick, noting dividend yield, cash flow and valuation metrics that could make the stock attractive for buy-and-hold investors. This supports longer-term demand from value-focused funds. Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
• Neutral Sentiment: Lilly’s large (up to $7B) in?vivo CAR?T deal underscores industry momentum toward genetic/in?vivo modalities — a structural trend that could increase competitive pressure in cell & gene spaces but also validates the big?pharma market for such platforms. Lilly’s CAR-T Kelonia deal cements Big Pharma’s in vivo push
• Neutral Sentiment: Coverage notes and commentary (Seeking Alpha) show some investor caution ahead of quarterly results, which can increase intraday selling or volatility even if the author ultimately holds. This amplifies near?term sentiment sensitivity around earnings. Gilead Sciences: Why I’m Tempted To Sell Ahead Of Q1 Earnings – But Won’t
• Neutral Sentiment: Recent market reports note Gilead’s share price has declined more than the broader market recently — a descriptive datapoint that can feed momentum selling but doesn’t by itself change fundamentals. Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
• Negative Sentiment: Zacks Research trimmed Q1–Q4 and FY2026 EPS estimates (small downgrades across quarters), lowering FY2026 from $8.34 to $8.29 in their model. Analyst cuts like these increase downside risk to guidance beats and can pressure the stock if investors reprice forward earnings.
• Negative Sentiment: Arcus halted a Gilead?partnered late?stage lung cancer trial — a direct negative for Gilead’s oncology partnership outcomes and future revenue potential from that program; trial halts often trigger re?rating until clarity on cause and next steps. Arcus halts Gilead-partnered late-stage trial for lung cancer drug
• Negative Sentiment: Relative valuation/peer comparisons (coverage favoring Bristol Myers over Gilead) highlight BMY’s cheaper valuation and stronger near?term growth narrative, which can shift investor allocation away from GILD in the large?cap biotech cohort. Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?

Gilead Sciences Stock Performance

Shares of GILD opened at $133.29 on Wednesday. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $157.29. The stock has a fifty day moving average price of $143.76 and a 200-day moving average price of $131.88. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The firm has a market cap of $165.44 billion, a PE ratio of 19.69, a P/E/G ratio of 1.79 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the prior year, the business posted $1.90 EPS. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 8.63 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were issued a dividend of $0.82 per share. The ex-dividend date was Friday, March 13th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.45%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on GILD shares. Cantor Fitzgerald lowered their target price on Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, April 10th. Bank of America set a $162.00 target price on Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, February 11th. Leerink Partners upped their target price on Gilead Sciences from $146.00 to $148.00 and gave the stock an “outperform” rating in a report on Wednesday, February 11th. Scotiabank upped their target price on Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a report on Wednesday, February 11th. Finally, Barclays started coverage on Gilead Sciences in a report on Friday, February 20th. They set an “equal weight” rating and a $155.00 target price for the company. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $157.35.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.